FGP
TARS icon

Freestone Grove Partners’s Tarsus Pharmaceuticals TARS Stock Holding History

Freestone Grove Partners’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-7,921
Closed -$439K – 779
2024
Q4 		$439K Buy
+7,921
New +$360K 0.01% 398

Other funds holding TARS

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Freestone Grove Partners's TARS Position: Q1 2025 in Review

Freestone Grove Partners sold out of Tarsus Pharmaceuticals (TARS) in Q1 2025, closing a stake of 7,921 shares — an estimated $439K sold.

Freestone Grove Partners first reported a position in TARS in Q4 2024 and held it in 1 quarter. The position peaked at $439K in Q4 2024. 194 funds tracked by Wall St. Rank hold TARS as of Q1 2025.

  • Freestone Grove Partners reported no remaining Tarsus Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Freestone Grove Partners sold 7,921 Tarsus Pharmaceuticals shares in Q1 2025, an estimated $439K.
  • Freestone Grove Partners first reported a position in Tarsus Pharmaceuticals in Q4 2024 and held it in 1 quarter.
  • Freestone Grove Partners's Tarsus Pharmaceuticals position peaked at $439K in Q4 2024.
  • 194 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q1 2025.

Based on Freestone Grove Partners's 13F filing for Q1 2025, filed 15 May 2025.